Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.

carfilzomib - Generic mfg.

dexamethasone - Generic mfg.

mezigdomide (CC-92480) - BMS

Carvykti (ciltacabtagene autoleucel) - J&J

Abecma (idecabtagene vicleucel) - BMS

http://www.ncbi.nlm.nih.gov/pubmed/42747560

Anna Bold; Henrik Niklas; Johannes Gärtner; Knut Wendelin; Marietta Truger; Nicola Lang; Simon Völkl; Stefan Knop; Susanne Strifler

Sep 17, 2026